Overuse of Health Care Services in the Management of Cancer: A Systematic Review

Medical Care

Volumn 55, Issue 7, 2017, Pages 723-733

  Baxi, Shrujal S ^a   Kale, Minal ^b   Keyhani, Salomeh ^c   Roman, Benjamin R ^a   Yang, Annie ^a   Derosa, Antonio P ^a   Korenstein, Deborah ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer care; health services; health services research; quality of care; utilization

Indexed keywords

CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); EMBASE; HEALTH SERVICE; HUMAN; INTERVENTION STUDY; MALIGNANT NEOPLASM; MEDLINE; META ANALYSIS (TOPIC); ONCOLOGY; PRIORITY JOURNAL; SCOPUS; STANDARD; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); WEB OF SCIENCE; HEALTH CARE QUALITY; HEALTH SERVICES RESEARCH; NEOPLASM;

HEALTH SERVICES MISUSE; HEALTH SERVICES RESEARCH; HUMANS; NEOPLASMS; QUALITY OF HEALTH CARE;

EID: 85021346825     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000734     Document Type: Conference Paper

References (82)

1. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103:117-128.
2. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27:3868-3874.
3. Prasad V, Mailankody S. The UK cancer drugs fund experiment and the US cancer drug cost problem: bearing the cost of cancer drugs until it is unbearable. Mayo Clin Proc. 2016;91:707-712.
4. Bernard DS, Farr SL, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol. 2011;29:2821-2826.
5. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12:933-980.
6. Ramsey SD. How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States. J Clin Oncol. 2007;25:175-179.
7. Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine national roundtable on health care quality. JAMA. 1998;280:1000-1005.
8. Institute of Medicine (IOM). Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington, DC: The National Academies Press; 2013.
9. Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA. 2012;307:1801-1802.
10. Schnipper LE, Lyman GH, Blayney DW, et al. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013;31:4362-4370.
11. Schnipper LE, Smith TJ, Raghavan D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30:1715-1724.
12. Korenstein D, Falk R, Howell EA, et al. Overuse of health care services in the United States: an understudied problem. Arch Intern Med. 2012;172:171-178.
13. Ramsey S, Schickedanz A. How should we define value in cancer care? Oncologist. 2010;15:1-4.
14. American Society of Clinical Oncology. The state of cancer care in America, 2016: a report by the American Society of Clinical Oncology. J Oncol Pract. 2016;12:339-383.
15. Kruse GR, Khan SM, Zaslavsky AM, et al. Overuse of colonoscopy for colorectal cancer screening and surveillance. J Gen Intern Med. 2015; 30:277-283.
16. Saini SD, Powell AA, Dominitz JA, et al. Developing and testing an electronic measure of screening colonoscopy overuse in a large integrated healthcare system. J Gen Intern Med. 2016;31:53-60.
17. Tan A, Kuo YF, Goodwin JS. Potential overuse of screening mammography and its association with access to primary care. Med Care. 2014;52:490-495.
18. Wilt TJ, Harris RP, Qaseem A. Screening for cancer: advice for highvalue care from the American College of Physicians. Ann Intern Med. 2015;162:718-725.
19. Kepka D, Breen N, King JB, et al. Overuse of papanicolaou testing among older women and among women without a cervix. JAMA Intern Med. 2014;174:293-296.
20. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
21. Akalin E, Yaka E, Yilmaz S, et al. Compliance with the Infectious Diseases Society of America guidelines for emergency management of febrile neutropenia in cancer patients. Acta Medica Mediterranea. 2015; 31:785-792.
22. Backhus LM, Farjah F, Varghese TK, et al. Appropriateness of imaging for lung cancer staging in a national cohort. J Clin Oncol. 2014;32: 3428-3435.
23. Barni S, Maiello E, Di Maio M, et al. Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. Lung Cancer. 2015;90:234-242.
24. Buhrkuhl DC, Karlsson MKP, Carter JM. An audit of platelet transfusion within the Wellington Cancer Centre. Intern Med J. 2012;42:65-70.
25. Choi WW, Williams SB, Gu XM, et al. Overuse of imaging for staging in low risk prostate cancer. J Urol. 2011;185:1645-1649.
26. Cooper M, Newman NA, Ibrahim AM, et al. Unnecessary tests and procedures in patients presenting with solid tumors of the pancreas. J Gastrointest Surg. 2013;17:1218-1223.
27. Crivello ML, Ruth K, Sigurdson ER, et al. Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population. Ann Surg Oncol. 2013;20:102-110.
28. Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011;117:2058-2066.
29. Ellis SD, Nielsen ME, Carpenter WR, et al. Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse. Prostate Cancer Prostatic Dis. 2015;18:173-181.
30. Erb CT, Su KW, Soulos PR, et al. Surveillance practice patterns after curative intent therapy for stage I non-small-cell lung cancer in the Medicare population. Lung Cancer. 2016;99:200-207.
31. Falchook AD, Hendrix LH, Chen RC. Guideline-discordant use of imaging during work-up of newly diagnosed prostate cancer. J Oncol Pract. 2015;11:e239-e246.
32. Falchook AD, Salloum RG, Hendrix LH, et al. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated medicare costs. Int J Radiat Oncol Biol Phys. 2014;89:243-248.
33. Feng YL, Lee CS, Chiu CC, et al. Appropriateness of parenteral nutrition usage in cancer patients. Nutr Cancer. 2015;67:1014-1017.
34. Geurts SME, de Vegt F, Siesling S, et al. Pattern of follow-up care and early relapse detection in breast cancer patients. Breast Cancer Res Treat. 2012;136:859-868.
35. Goffredo P, Thomas SM, Dinan MA, et al. Patterns of use and cost for inappropriate radioactive iodine treatment for thyroid cancer in the United States: use and misuse. JAMA Intern Med. 2015;175:638-640.
36. Guy GP, Lipscomb J, Gillespie TW, et al. Variations in guidelineconcordant breast cancer adjuvant therapy in rural Georgia. Health Serv Res. 2015;50:1088-1108.
37. Haas JS, Phillips KA, Liang SY, et al. Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract. 2011;7:e1s-e7s.
38. Haddad D, Garvey EM, Mihalik L, et al. Preoperative imaging for earlystage cutaneous melanoma: predictors, usage, and utility at a single institution. Am J Surg. 2013;206:979-986.
39. Hahn EE, Hays RD, Kahn KL, et al. Use of imaging and biomarker tests for posttreatment care of early-stage breast cancer survivors. Cancer. 2013;119:4316-4324.
40. Hahn EE, Tang T, Lee JS, et al. Use of imaging for staging of early-stage breast cancer in two integrated health care systems: adherence with a Choosing Wisely recommendation. J Oncol Pract. 2015;11:e320-e328.
41. Hahn EE, Tang T, Lee JS, et al. Use of posttreatment imaging and biomarkers in survivors of early-stage breast cancer: inappropriate surveillance or necessary care? Cancer. 2016;122:908-916.
42. Han D, Hogeveen S, Sweet Goldstein M, et al. Is knowledge translation adequate? A quality assurance study of staging investigations in early stage breast cancer patients. Breast Cancer Res Treat. 2012;132:1-7.
43. Lavery HJ, Brajtbord JS, Levinson AW, et al. Unnecessary imaging for the staging of low-risk prostate cancer is common. Urology. 2011; 77:274-278.
44. Linkugel A, Margenthaler J, Dull B, et al. Staging studies have limited utility for newly diagnosed stage I-II breast cancer. J Surg Res. 2015;196:33-38.
45. Lipitz-Snyderman A, Sima CS, Atoria CL, et al. Physician-driven variation in nonrecommended services among older adults diagnosed with cancer. JAMA Intern Med. 2016;176:1541-1548.
46. Livingstone E, Krajewski C, Eigentler TK, et al. Prospective evaluation of follow-up in melanoma patients in Germany-results of a multicentre and longitudinal study. Eur J Cancer. 2015;51:653-667.
47. Lochard-Lefrancois A, Blandin AC, Fagnoni P, et al. Appropriate cytotoxic drugs usages in solid tumors: impact of appropriate use referentials. Le Pharmacien Hospitalier et Clinicien. 2012;47:e1-e7.
48. Makarov DV, Desai R, Yu JB, et al. Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat. Health Aff (Millwood). 2012;31:730-740.
49. Makarov DV, Desai RA, Yu JB, et al. The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the Medicare population. J Urol. 2012;187:97-102.
50. Makarov DV, Hu EY, Walter D, et al. Appropriateness of prostate cancer imaging among veterans in a delivery system without incentives for overutilization. Health Serv Res. 2016;51:1021-1051.
51. Makarov DV, Loeb S, Ulmert D, et al. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst. 2013;105:1306-1313.
52. Makarov DV, Soulos PR, Gold HT, et al. Regional-level correlations in inappropriate imaging rates for prostate and breast cancers: potential implications for the Choosing Wisely campaign. JAMA Oncol. 2015; 1:185-194.
53. Massarweh NN, Park JO, Bruix J, et al. Diagnostic imaging and biopsy use among elderly Medicare beneficiaries with hepatocellular carcinoma. J Oncol Pract. 2011;7:155-160.
54. Miller DC, Murtagh DS, Suh RS, et al. Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer. J Urol. 2011;186:844-849.
55. Palvolgyi R, Daskivich TJ, Chamie K, et al. Bone scan overuse in staging of prostate cancer: an analysis of a Veterans Affairs cohort. Urology. 2011;77:1330-1336.
56. Panageas KS, Sima CS, Liberman L, et al. Use of high technology imaging for surveillance of early stage breast cancer. Breast Cancer Res Treat. 2012;131:663-670.
57. Parmar AD, Sheffield KM, Vargas GM, et al. Quality of post-treatment surveillance of early stage breast cancer in Texas. Surgery. 2013;154: 214-225.
58. Paulson EC, Veenstra CM, Vachani A, et al. Trends in surveillance for resected colorectal cancer, 2001-2009. Cancer. 2015;121:3525-3533.
59. Peeraphatdit T, Naksuk N, Phatharacharukul P, et al. Adherence to diagnostic guidelines of hepatocellular carcinoma: 12-year experience in a veterans affairs medical center. Eur J Gastroenterol Hepatol. 2015;27: 846-852.
60. Porten SP, Smith A, Odisho AY, et al. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:246-251.
61. Prasad SM, Gu XM, Lipsitz SR, et al. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer. 2012;118:1260-1267.
62. Ramsey SD, Fedorenko C, Chauhan R, et al. Baseline estimates of adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely initiative among patients with cancer enrolled with a large regional commercial health insurer. J Oncol Pract. 2015;11:338-343.
63. Ramsey SD, Henry NL, Gralow JR, et al. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol. 2015;33:149-155.
64. Ross I, Womble P, Ye J, et al. MUSIC: patterns of care in the radiographic staging of men with newly diagnosed low risk prostate cancer. J Urol. 2015;193:1159-1162.
65. Sacks W, Wong RM, Bresee C, et al. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer. Thyroid. 2015;25:377-385.
66. Salloum RG, Hornbrook MC, Fishman PA, et al. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer. 2012;118:5644-5651.
67. Sammon JD, Abdollah F, Reznor G, et al. Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer. Eur Urol. 2015;68:32-39.
68. Sawazaki H, Sengiku A, Imamura M, et al. Feedback on baseline use of staging images is important to improve image overuse with newly diagnosed prostate cancer patients. Asian Pac J Cancer Prev. 2014;15:1707-1710.
69. Schroeck FR, Kaufman SR, Jacobs BL, et al. Regional variation in quality of prostate cancer care. J Urol. 2014;191:957-962.
70. Schroeck FR, Kaufman SR, Jacobs BL, et al. Technology diffusion and prostate cancer quality of care. Urology. 2014;84:1066-1072.
71. Segal JB, Bridges JF, Chang HY, et al. Identifying possible indicators of systematic overuse of health care procedures with claims data. Med Care. 2014;52:157-163.
72. Shahinian VB, Kuo YF. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer. BMC Urol. 2015;15:25-30.
73. Shih YC, Xu Y, Dong W, et al. First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer. Breast Cancer Res Treat. 2014;144: 417-425.
74. Simonato A, Varca V, Gacci M, et al. Adherence to guidelines among Italian urologists on imaging preoperative staging of low-risk prostate cancer: results from the MIRROR (Multicenter Italian Report on Radical prostatectomy Outcomes and Research) study. Adv Urol. 2012. article ID 651061, 6 pages.
75. Simos D, Catley C, Van Walraven C, et al. Imaging for distant metastases in women with early-stage breast cancer: a population-based cohort study. CMAJ. 2015;187:E387-E397.
76. Simos D, Hutton B, Clemons M. Are physicians choosing wisely when imaging for distant metastases in women with operable breast cancer? J Oncol Pract. 2015;11:62-68.
77. Swisher-McClure S, Pollack CE, Christodouleas JP, et al. Variation in use of androgen suppression with external-beam radiotherapy for nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83:8-15.
78. Vazin A, Davarpanah MA, Ghalesoltani S. Antifungal agent utilization evaluation in hospitalized neutropenic cancer patients at a large teaching hospital. Drug Healthc Patient Saf. 2015;7:97-102.
79. Weeks JC, Uno H, Taback N, et al. Interinstitutional variation in management decisions for treatment of 4 common types of cancer: a multi-institutional cohort study. Ann Intern Med. 2014;161:20-30.
80. Bergstrom R. Drivers of the cost of cancer care. Lancet Oncol. 2012; 13:14-15.
81. Mack JW, Chen LH, Cannavale K, et al. End-of-life care intensity among adolescent and young adult patients with cancer in Kaiser Permanente southern California. JAMA Oncol. 2015;1:592-600.
82. Prigerson HG, Bao Y, Shah MA, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1: 778-784.